After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Good morning. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of having Recursion Pharmaceuticals up ...

In a video call with Polygon, Pluribus creator Gilligan, Gordon Smith (director, writer, executive Producer), and Alison ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...

Business leaders can’t outsource mathematical thinking to AI without sacrificing judgment, because real-world business ...

The answer lies in a simple but powerful mathematical idea called “the house edge”: a small, systematic statistical advantage ...